- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01252212
Adherence, Improvement Measure (AIM) System (AIM)
November 18, 2013 updated by: University of California, San Francisco
Adherence, Improvement Measure (AIM) System; Challenge Topic: 10-MH-101
In this project, we will work directly with underserved patients in a safety-net setting to conduct a randomized clinical trial of standard-of-care adherence counseling versus a novel adherence intervention embedded in an existing PHR that uses cellular phone short message service (SMS) reminders and patient responses to the reminders.
We will compare adherence rates in both arms as assessed by antiretroviral medication concentrations in hair samples and self-report; clinical outcomes will also be compared in the two arms.
The project will examine medication adherence for antiretroviral medications and treatments of common conditions such as depression, hypertension, diabetes and hypercholesterolemia.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
99
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94110
- Ward 86, San Francisco General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Older than 18
- Evidence of HIV-1 infection, based on patient's medical history or results of laboratory tests
- Detectable Viral Load, based on patient's medical record
- Receiving primary medical care at the AIDS Program at SFGH
- Able and willing to give informed consent to be randomized to study arms
- Willing to use the patient portal
- Has a cell phone with ability to receive and send unlimited SMS texts, Patient of the HIV/AIDS Clinic at ward 86, SFGH
Exclusion Criteria:
Failure to meet inclusion criteria
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Receiving SMS alerts
The patients randomized to this arm will have a SMS message sent to them regarding medication adherence for antiretroviral medications, anti-hypertensive medications, anti-depressants, hyperglycemic controlling medications and hypercholesterolemia controlling medications as well as life style supportive suggestions.
|
SMS messages to cell phones.
Other Names:
|
|
Active Comparator: No SMS messages
The patients randomized to this arm will have a SMS message sent to them regarding healthy life style supportive suggestions.
|
In this arm, patients will be sent supportive lifestyle suggestions to their phone using SMS technology but will not be sent a reminder regarding their medication adherence.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
HIV viral load
Time Frame: 12 month
|
The primary analyses of the 12-month trial data will compare the two study groups with respect to (i) change from baseline in CD4 T-cell count; and (ii) proportion of patients whose HIV viral load (VL) level is detectable.
We will use repeated-measures analysis techniques to estimate longitudinal prevalence at the population level (via generalized estimating equations) and at the individual levels (via generalized linear mixed models)[25].
|
12 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Level of antiretroviral medication in hair
Time Frame: 12 month
|
We will evaluate the antiretroviral level in hair samples from patients to determine compliance with medications.
|
12 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: James Kahn, MD, University of California, San Francisco
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2010
Primary Completion (Actual)
February 1, 2012
Study Completion (Actual)
December 1, 2012
Study Registration Dates
First Submitted
November 30, 2010
First Submitted That Met QC Criteria
November 30, 2010
First Posted (Estimate)
December 2, 2010
Study Record Updates
Last Update Posted (Estimate)
November 20, 2013
Last Update Submitted That Met QC Criteria
November 18, 2013
Last Verified
November 1, 2013
More Information
Terms related to this study
Other Study ID Numbers
- 10-00019
- 1RC1MH088341 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AIDS
-
GlaxoSmithKlineCompletedAIDS | AIDS VaccinesBelgium
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
Prof. Dr. Jörg LeuppiNot yet recruitingAudiovisual Aids | The Effect of Audio-visual Aids on Bowel CleanlinessSwitzerland
-
Cell Energy Life Sciences Group Co. LTDBeijing YouAn Hospital; Beijing 302 Hospital; Shenzhen Third People's Hospital; Fifth Hospital of Shijiazhuang CityRecruiting
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI)Not yet recruitingSkin Kaposi Sarcoma | AIDS-Related Kaposi SarcomaUnited States
-
ViiV HealthcarePfizerCompleted
-
University of ArizonaCompletedHearing AidsUnited States
-
NorthShore University HealthSystemCompletedCognitive AidsUnited States
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLCCompletedAIDS-related Peripheral/Systemic Lymphoma | AIDS-related Diffuse Large Cell Lymphoma | AIDS-related Diffuse Mixed Cell Lymphoma | AIDS-related Diffuse Small Cleaved Cell Lymphoma | AIDS-related Immunoblastic Large Cell Lymphoma | AIDS-related Lymphoblastic Lymphoma | AIDS-related Small Noncleaved... and other conditionsZimbabwe, Kenya
-
Sodra Alvsborgs HospitalCompleted
Clinical Trials on SMS medication adherence
-
The Hong Kong Polytechnic UniversityCastle Peak Hospital; Kwai Chung Hospital, Hong KongCompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform DisorderHong Kong
-
Mbarara University of Science and TechnologyRecruiting
-
University of PennsylvaniaActive, not recruitingHypertension and HyperlipidemiaUnited States
-
University Hospital, MontpellierUnknown
-
Rhode Island HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
University of WashingtonAmerican Association of Diabetes EducatorsUnknown
-
Massachusetts General HospitalRecruitingStroke | Ischemic Stroke | Intracerebral Haemorrhage | TIA (Transient Ischemic Attack)United States
-
University of LeicesterTerminatedHypertension | Diabetes Mellitus, Type 2 | Medication AdherenceUnited Kingdom
-
Collabree AGUniversity Hospital, Basel, SwitzerlandCompletedHypertension | Medication AdherenceSwitzerland
-
Anjali Raja BeharelleMediService AGCompletedHypertension | Medication AdherenceSwitzerland